NBIX vs NKE · P/E 45, rev $1.77B vs P/E 35, rev $46.40B
Neurocrine Biosciences Inc (NBIX) versus Nike Inc (NKE) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Nike Inc (NKE) is a footwear & accessories company listed on US. It is led by Elliott J. Hill.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported NKE revenue for 2026-05-31 was $46.40B. Net income was $3.11B. Revenue was up 0.2% from 2025-05-31 to 2026-05-31. NKE currently screens at market cap $110.14B and trailing P/E 34.6.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. NKE currently screens at market cap $110.14B and trailing P/E 34.6.
Not investment advice. Open the NBIX and NKE stock pages for the full models.
Not investment advice.